the molecular differences between younger versus older er-positive and her2-negative breast cancers
Published 1 year ago • 2.3K plays • Length 3:08Download video MP4
Download video MP3
Similar videos
-
2:14
clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
-
0:35
key challenge associated with the management of hr /her2- breast cancer
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
1:51
ameera-3: serd for er her2- breast cancer
-
2:05
important considerations in the management of hr , her2-negative early breast cancer
-
4:53
comparing therapy benefit from initially her2 positive or negative metastatic breast cancer patients
-
0:50
serds for patients with er /her2- breast cancer
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
2:55
differential long-term benefit of adjuvant tamoxifen in er /her2- premenopausal postmenopausal bc
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
1:08
findings indicate her2-low and her2-negative breast cancer are biology indistinct
-
0:45
luminal a vs. luminal b breast cancer: key differences
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
3:01
alternate: neoadjuvant chemotherapy in er her2- breast cancer
-
2:14
management of premenopausal hr /her2- breast cancer with micro-metastasis
-
25:14
metastatic her2 negative breast cancer: emerging novel treatment strategies
-
6:55
mafalda oliveira, sabcs 2022: camizestrant vs fulvestrant for advanced er her2- breast cancer
-
1:49
early breast cancer: do we need chemotherapy in low genomic/high clinical risk (er /her2-)?
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer